151 related articles for article (PubMed ID: 16846804)
1. The impact of interferon-beta treatment on the blood-brain barrier.
Kraus J; Oschmann P
Drug Discov Today; 2006 Aug; 11(15-16):755-62. PubMed ID: 16846804
[TBL] [Abstract][Full Text] [Related]
2. IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier.
Niemelä J; Ifergan I; Yegutkin GG; Jalkanen S; Prat A; Airas L
Eur J Immunol; 2008 Oct; 38(10):2718-26. PubMed ID: 18825744
[TBL] [Abstract][Full Text] [Related]
3. Interferon-beta: mechanism of action and dosing issues.
Markowitz CE
Neurology; 2007 Jun; 68(24 Suppl 4):S8-11. PubMed ID: 17562848
[TBL] [Abstract][Full Text] [Related]
4. The blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting.
Correale J; Villa A
Autoimmunity; 2007 Mar; 40(2):148-60. PubMed ID: 17453713
[TBL] [Abstract][Full Text] [Related]
5. Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption.
Veldhuis WB; Floris S; van der Meide PH; Vos IM; de Vries HE; Dijkstra CD; Bär PR; Nicolay K
J Cereb Blood Flow Metab; 2003 Sep; 23(9):1060-9. PubMed ID: 12973022
[TBL] [Abstract][Full Text] [Related]
6. Modern multiple sclerosis treatment - what is approved, what is on the horizon.
Pilz G; Wipfler P; Ladurner G; Kraus J
Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508
[TBL] [Abstract][Full Text] [Related]
7. [Blood-brain barrier in multiple sclerosis: mechanisms of its breakdown and repair].
Kanda T
Nihon Rinsho; 2003 Aug; 61(8):1402-8. PubMed ID: 12962030
[TBL] [Abstract][Full Text] [Related]
8. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
[TBL] [Abstract][Full Text] [Related]
9. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F
Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668
[TBL] [Abstract][Full Text] [Related]
10. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
Comi G
Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
[TBL] [Abstract][Full Text] [Related]
11. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis.
Ross TM; Martinez PM; Renner JC; Thorne RG; Hanson LR; Frey WH
J Neuroimmunol; 2004 Jun; 151(1-2):66-77. PubMed ID: 15145605
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic role of beta-interferons in multiple sclerosis.
Javed A; Reder AT
Pharmacol Ther; 2006 Apr; 110(1):35-56. PubMed ID: 16229894
[TBL] [Abstract][Full Text] [Related]
13. The gap between effect of drugs and effectiveness of treatments.
Sorensen PS
J Neurol Sci; 2007 Aug; 259(1-2):128-32. PubMed ID: 17362994
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
15. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy.
Singh MK; Scott TF; LaFramboise WA; Hu FZ; Post JC; Ehrlich GD
J Neurol Sci; 2007 Jul; 258(1-2):52-9. PubMed ID: 17467740
[TBL] [Abstract][Full Text] [Related]
16. Differential susceptibility of cerebral and cerebellar murine brain microvascular endothelial cells to loss of barrier properties in response to inflammatory stimuli.
Silwedel C; Förster C
J Neuroimmunol; 2006 Oct; 179(1-2):37-45. PubMed ID: 16884785
[TBL] [Abstract][Full Text] [Related]
17. Interferons and multiple sclerosis: is it plausible that beta-IFN treatment could influence the risk of cancer among MS patients?
Kingwell E; Tremlett H
Expert Rev Neurother; 2009 Sep; 9(9):1263-5. PubMed ID: 19769440
[No Abstract] [Full Text] [Related]
18. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR
Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134
[TBL] [Abstract][Full Text] [Related]
19. The blood-brain barrier in cortical multiple sclerosis lesions.
van Horssen J; Brink BP; de Vries HE; van der Valk P; Bø L
J Neuropathol Exp Neurol; 2007 Apr; 66(4):321-8. PubMed ID: 17413323
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy for multiple sclerosis: progress and prospects.
Palmer AM
Curr Opin Investig Drugs; 2009 May; 10(5):407-17. PubMed ID: 19431073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
